# Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)

> **NCT02719990** · PHASE2 · TERMINATED · sponsor: **Versartis Inc.** · enrollment: 36 (actual)

## Conditions studied

- Adult Growth Hormone Deficiency (AGHD)

## Interventions

- **DRUG:** somavaratan

## Key facts

- **NCT ID:** NCT02719990
- **Lead sponsor:** Versartis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-11
- **Primary completion:** 2018-01-11
- **Final completion:** 2018-01-11
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Phase 3 clinical trial of somavaratan in pediatric growth hormone deficiency (PGHD) did not meet its primary endpoint of non-inferiority.
- **Last updated:** 2023-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02719990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02719990, "Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02719990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*